| Literature DB >> 34974843 |
P S Rakesh1, Shibu Balakrishnan2, M Sunilkumar3, K G Alexander4, Shibu Vijayan5, Venkatesh Roddawar6, P P Pramod Kumar7, Jyothi Kailash7, Akhilesh Kunoor8, Midhun Rajiv9, Anoop John9, Rakesh Ramachandran9.
Abstract
BACKGROUND: More than half of the TB patients in India seek care from the private sector. Two decades of attempts by the National TB Program to improve collaboration between the public and private sectors have not worked except in a few innovative pilots. The System for TB Elimination in Private Sector (STEPS) evolved in 2019 as a solution to ensure standards of TB care to every patient reaching the private sector. We formally evaluated the STEPS to judge the success of the model in achieving its outcomes and to inform decisions about scaling up of the model to other parts of the country.Entities:
Mesh:
Year: 2022 PMID: 34974843 PMCID: PMC8720462 DOI: 10.1186/s12913-021-07342-y
Source DB: PubMed Journal: BMC Health Serv Res ISSN: 1472-6963 Impact factor: 2.655
Fig. 1Logic Framework for STEPS
Assessment of infrastructure and functionality of STEPS Centers (N = 30)
| Checklist | Number (%) |
|---|---|
| Presence of dedicated STEPS Lead for the hospital | 30 (100%) |
| STEPS Lead trained in STCI & NTEP | 29 (96.6%) |
| Training for doctors on STCI conducted | 28 (93.3%) |
| An internal circular to all hospital staff by Administration regarding STEPS | 22 (73.3%) |
| Details of STEPS services displayed for public | 17 (56.6%) |
| Receptionist/Patient Help Desk aware of STEPS centre | 27 (90%) |
| Access to Molecular testing for TB available | 26 (86.7%) |
| STEPS Lead demonstrated process of ensuring treatment support to patients with the help of documents | 26 (86.7%) |
| STEPS Lead explained patient data using NIKSHAY | 29 (96.7%) |
| Airborne Infection Control Kit for issuing to patients available | 23 (76.7%) |
| NTEP drugs stock matching with stock register ( | 14/14 (100%) * |
| Cough hygiene IECs displayed at patient waiting areas | 24 (80%) |
| Review of TB activities of STEPS centre by Hospital Administration | 19 (63.3%) |
| System for notification of all cases in NIKSHAY with triangulation of clinical data with pharmacy data, lab data | 17 (56.7%) |
| Participated in quarterly review of STEPS by district private hospital consortium (PHOTON) | 24 (80%) |
*14 out of 30 hospitals were stocking NTEP drugs, 9 were getting the drugs as and when needed from NTEP because of low case load and 7 hospitals were prescribing only private anti TB drugs
Validation of the patient data in NIKSHAY by telephonic interview of TB patients availing services from STEPS centres (N = 57)
| Data points | Information in NIKSHAY consistent with Patient Interviews & record verification |
|---|---|
| Date of TB diagnosis | 56/57 (98.2% |
| Basis of TB diagnosis | 54/57 (94.7%) |
| Date of treatment initiation | 57/ 57 (100%) |
| HIV status | 48 / 48 (100%) |
| Date of UDST | 28/29 (96.5%) |
| DBT benefit received | 31/31 (100%) |
| Outcome Reported | 38/38 (100%) |
Comparison of quality of patient care indicators (2018,2019, 2020)
| Indicator | 2018 | 2019 | 2020 |
|---|---|---|---|
| Number of TB cases notified by the private sector | 3981 | 5003 | 5795 |
| Proportion of TB cases (out of total notified) notified from private sector | 16.2% | 19.6% | 28.9% |
| Number (%) of microbiologically confirmed cases among notified TB | 995 (25%) | 1951 (39%) | 2202 (38%) |
| Number (%) of notified patients offered Rifampicin drug resistance testing at baseline | 637 (16%) | 1951 (39%) | 3187 (55%) |
| Number (%) of notified TB patients who know their HIV status | 1672 (42%) | 4102 (82%) | 4809 (83%) |
| Number (%) of notified patients received direct benefit transfer | 1273 (32%) | 3552 (71%) | 4056 (70%) |
| Number (%) of notified patients whose treatment outcome was reported in Nikshay | 1393 (35%) | 4952 (99%) | |
| Number (%) of notified patients who had successful treatment outcome reported in Nikshay | 1324 (33%) | 4402 (88%) |
Cost for NTEP for implementation of STEPS
| Cost Category | Description | Average cost for 12 months in USD |
|---|---|---|
| 1. | Salary of PPM Lead and 5 city officers of Intermediary agency | 49,000 |
| Field Expenses of PPM Lead and 5 city officers of Intermediary agency | 31,000 | |
| 2. | Training, Retraining and Sensitisation of doctors and STEPS Leads | 27,788 |
| 3. | Specimen pick up transportation from private hospitals to GeneXpert site | 1669 |
| 14 additional Lab Technician posted at GeneXpert site to handle extra specimens from private sector | 30,333 | |
| 6604 GeneXpert cartridge for testing additional samples from private sector* | 110,066 | |
| 10,000 Number of Chest X ray Reimbursed for diagnosing TB to private hospitals* | 27,776 | |
| 4. | 2000 additional patients from private sector put on NTEP drugs* | 28,694 |
| Air born Infection Control Kits provided* | 5555 | |
| 5. | Meetings of Coalition and Consortiums | 7778 |
| Additional expenses on Supervision, Monitoring & Evaluation | 1388 | |
| Printing of directory, Patient information booklets, IEC materials | 6944 | |
| Additional expense for supply chain management | 10,933 | |
| 6. | Additional Incentive for Notification to private hospitals | 12,597 |
| Additional incentive for providing outcome to private hospitals | 24,194 | |
| Additional Incentive to the patient getting treatment from private sector | 36,250 | |
| 411,965 | ||
| 136 | ||
| 67 | ||
Estimated Cost sheet for a private hospital diagnosing 100 TB patients in a year for implementing STEPS
| Additional Expenses/ Business Loss to private hospital (USD) | Additional Returns to private hospitals (USD) per year |
|---|---|
| Telephone charges = (0.02 USD per call *1000 calls) = 20USD | 18 TB patients, who were previously lost to follow up, return to hospital/spoke centre for average of 5 additional visits (3 USD consultation fee & 3.5 USD for follow up investigations and treatment of co-morbidity * 18 * 5 visits) = 585 USD |
| Loss due to forgone profit in TB Drugs = (2.5USD *100) =250 | |
Loss due to forgone profit in Molecular tests for baseline Rifampicin testing (2USD*100) = 200 USD | Incentive for Providing Treatment Outcome (7 USD*60 additional outcome) = 420 USD |
| 6000 Minutes of staff Nurse (12.5 working days) =103 USD | Incentive for TB Notification (7 USD*20 additional notification) = 140 USD |
a Additional returns to hospitals through increased client load through referral of friends and relatives by loyal customers not calculated
Cost details for a TB patient who would have been Lost to Follow Up from a private hospital prior to STEPS implementation and now availed all services through STEPS
| Additional Expenses for the Patient | Cost Saving/ Additional Income for the patient |
|---|---|
| Additional 5 consultation at private hospital/ spoke centre (3USD for consultation fee, 10 USD for follow up investigation and treatment of co-morbidity, 4 USD for travel per visit to hospital/spoke canter) = 5*17 USD = 85 USD | TB Drugs - 17 USD Expense for GeneXpert - 28 USD Expense for X-ray − 03 USD AIC Kit - 02 USD DBT - 42 USD |
a Indirect cost other than travel not included, $cost saving through improved health not estimated